Compare AbbVie Inc (ABBV) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Futu Holdings Ltd — how do they compare? AbbVie Inc trades at $249.52 (market cap $441.94B), while Futu Holdings Ltd trades at $105.1 (market cap $14.74B). The key difference: AbbVie Inc is far larger — about 30× Futu Holdings Ltd's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | FUTU | |
|---|---|---|
Market Cap | $441.94B | $14.74B |
Sector | Health | Financials |
52-Week High | $263.58 | $199.04 |
52-Week Low | $197.38 | $89.76 |
Enterprise Value | $506.19B | $14.59B |
Dividend Yield | 2.77% | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Futu Holdings Limited (FUTU) trades at $108.70, showing modest daily movement with a slight decline of 0.29%. The stock exhibits a bullish technical trend, supported by moving averages, while recent earnings have been mixed with two misses and one beat against expectations. Strong revenue growth and profitability margins highlight solid fundamental performance, though the company faces significant legal and regulatory scrutiny.
The outlook for FUTU is cautiously optimistic, driven by robust financial health and analyst support, but overshadowed by ongoing securities class action lawsuits alleging regulatory compliance failures. Key risks include legal liabilities and market sentiment pressure, while opportunities lie in sustained earnings growth and favorable valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
